You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 167 No. 18, October 8, 2007 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Investigation
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (14)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Bacterial Infections
 •Critical Care/ Intensive Care Medicine
 •Adult Critical Care
 •Anesthesia
 •Cardiovascular System
 •Prognosis/ Outcomes
 •Drug Therapy
 •Adverse Effects
 •Cardiac Diagnostic Tests
 •Hematology/ Hematologic Malignancies
 •Anemias
 •Hematology, Other
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Benzocaine-Induced Methemoglobinemia Based on the Mayo Clinic Experience From 28 478 Transesophageal Echocardiograms

Incidence, Outcomes, and Predisposing Factors

Garvan C. Kane, MD, PhD; Suzette M. Hoehn, RN; Thomas R. Behrenbeck, MD, PhD; Sharon L. Mulvagh, MD

Arch Intern Med. 2007;167(18):1977-1982.

Background  The potentially life-threatening condition of methemoglobinemia is characterized by cyanosis, low pulse oximetric readings, and normal arterial PO2 values. Acquired methemoglobinemia has been linked to the use of the topical anesthetic benzocaine in endoscopic procedures, including transesophageal echocardiography (TEE). Yet, the incidence of benzocaine-induced methemoglobinemia with TEE and the clinical factors associated with its development are unclear.

Methods  All cases of methemoglobinemia complicating TEE at our institution (from January 1, 1999, to July 1, 2006) were identified by a comprehensive review of medical records and echocardiography and pharmacy databases.

Results  During 90 months among 28 478 TEEs, 19 cases of methemoglobinemia were identified, with a mean ± SD methemoglobin level of 32% ± 15%. All patients were cyanotic, with low oxygen saturations. Eighteen of 19 patients received methylene blue (mean ± SD dose, 1.3 ± 0.4 mg/kg of body weight), with resolution of symptoms and signs. One of 19 cases resolved spontaneously. Compared with a random sample of 190 patients undergoing TEE, the age, sex, body mass index, left ventricular systolic function, and dose of sedation (midazolam hydrochloride, fentanyl citrate, or both) were similar in the 2 groups. However, study patients who developed methemoglobinemia were more likely to be hospitalized (89.5% vs 57.6%, P =.005), be anemic (84.2% vs 44.7%, P =.002), and have active systemic infection (68.4% vs 6.8%; P < .001) at the time of TEE compared with the random control cohort.

Conclusions  In a large series of patients undergoing TEE, the incidence of methemoglobinemia is low (1 case per 1499 [0.067%; 95% confidence interval, 0.040%-0.100%]) and has a good outcome if promptly recognized and treated. Clinical factors associated with the development of methemoglobinemia include sepsis, anemia, and hospitalization. Minimizing or avoiding the use of benzocaine in these patients is recommended.


Author Affiliations: Echocardiography Laboratory, Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Severe Methemoglobinemia From Topical Benzocaine 7.5% (Baby Orajel) Use for Teething Pain in a Toddler
Bong et al.
CLIN PEDIATR 2009;48:209-211.
 





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.